BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

4481

524348

AARTIDRUGS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

AARTI DRUGS LTD. performance

Today’s low

Today’s high

₹ 347.10 ₹ 368.60
₹ 350.30

52 week low

52 week high

₹ 312.00 ₹ 635.00
₹ 350.30

Open Price

₹ 368.60

Prev. Close

₹ 365.85

Volume (Shares)

99833.00

Total traded value

₹ 349.71

Upper Circuit

₹ 439.00

Lower Circuit

₹ 292.70

info

AARTI DRUGS LTD. Share Price Update

As of the latest trading session, AARTI DRUGS LTD. share price is currently at ₹ 350.8, which is down by ₹ -15.05 from its previous closing. Today, the stock has fluctuated between ₹ 347.10 and ₹ 368.60. Over the past year, AARTI DRUGS LTD. has achieved a return of -26.93 %. In the last month alone, the return has been 2.69 %. Read More...

AARTI DRUGS LTD. fundamentals


  • Market cap (Cr)

    3,245.80

  • P/E Ratio (TTM)

    25.49

  • Beta

    0.74

  • Book Value / share

    126.17

  • Return on equity

    12.39%

  • EPS (TTM)

    14.35

  • Dividend yield

    0.27%

  • Net profit/quarter (Cr)

    38.53

info icon alternate text
  • Market cap (Cr)

    3,224.60

  • P/E Ratio (TTM)

    25.49

  • Beta

    0.71

  • Book Value / share

    126.17

  • Return on equity

    12.39%

  • EPS (TTM)

    14.35

  • Dividend yield

    0.27%

  • Net profit/quarter (Cr)

    38.53

info icon alternate text

AARTI DRUGS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 514.54
Operating Expense 473.88
Net Profit 38.53
Net Profit Margin (%) 7.48
Earnings Per Share (EPS) 4.22
EBITDA 71.62
Effective Tax Rate (%) 25.94
Particulars SEP 2024 (Values in Cr)
Revenue 543.09
Operating Expense 502.58
Net Profit 30.39
Net Profit Margin (%) 5.59
Earnings Per Share (EPS) 3.33
EBITDA 59.92
Effective Tax Rate (%) 25.67
Particulars JUN 2024 (Values in Cr)
Revenue 492.96
Operating Expense 457.90
Net Profit 26.91
Net Profit Margin (%) 5.45
Earnings Per Share (EPS) 2.93
EBITDA 54.33
Effective Tax Rate (%) 23.46
Particulars MAR 2024 (Values in Cr)
Revenue 559.53
Operating Expense 510.90
Net Profit 36.14
Net Profit Margin (%) 6.45
Earnings Per Share (EPS) 3.93
EBITDA 70.17
Effective Tax Rate (%) 27.34
Particulars DEC 2023 (Values in Cr)
Revenue 538.21
Operating Expense 497.02
Net Profit 31.62
Net Profit Margin (%) 5.87
Earnings Per Share (EPS) 3.44
EBITDA 61.42
Effective Tax Rate (%) 26.24
Particulars MAR 2024 (Values in Cr)
Revenue 2266.91
Operating Expense 2078.60
Net Profit 141.88
Net Profit Margin (%) 6.25
Earnings Per Share (EPS) 15.35
EBITDA 270.31
Effective Tax Rate (%) 26.28
Particulars MAR 2023 (Values in Cr)
Revenue 2497.97
Operating Expense 2295.39
Net Profit 152.81
Net Profit Margin (%) 6.11
Earnings Per Share (EPS) 16.50
EBITDA 284.63
Effective Tax Rate (%) 25.38
Particulars MAR 2022 (Values in Cr)
Revenue 2251.17
Operating Expense 2000.44
Net Profit 195.00
Net Profit Margin (%) 8.66
Earnings Per Share (EPS) 21.04
EBITDA 322.95
Effective Tax Rate (%) 23.67
Particulars MAR 2021 (Values in Cr)
Revenue 1914.89
Operating Expense 1583.82
Net Profit 257.71
Net Profit Margin (%) 13.45
Earnings Per Share (EPS) 27.65
EBITDA 407.92
Effective Tax Rate (%) 23.68
Particulars MAR 2020 (Values in Cr)
Revenue 1634.92
Operating Expense 1469.39
Net Profit 135.67
Net Profit Margin (%) 8.29
Earnings Per Share (EPS) 58.12
EBITDA 253.84
Effective Tax Rate (%) 22.46
Particulars MAR 2024 (Values in Cr)
Book Value / Share 139.40
ROE % 13.87
ROCE % 14.97
Total Debt to Total Equity 0.47
EBITDA Margin 12.85
Particulars MAR 2023 (Values in Cr)
Book Value / Share 128.77
ROE % 14.93
ROCE % 15.36
Total Debt to Total Equity 0.52
EBITDA Margin 11.47
Particulars MAR 2022 (Values in Cr)
Book Value / Share 111.92
ROE % 21.03
ROCE % 20.33
Total Debt to Total Equity 0.46
EBITDA Margin 13.82
Particulars MAR 2021 (Values in Cr)
Book Value / Share 98.01
ROE % 35.81
ROCE % 33.38
Total Debt to Total Equity 0.47
EBITDA Margin 20.66
Particulars MAR 2020 (Values in Cr)
Book Value / Share 280.04
ROE % 23.65
ROCE % 20.73
Total Debt to Total Equity 0.75
EBITDA Margin 15.03
Particulars MAR 2024 (Values in Cr)
Book Value / Share 127.83
ROE % 12.39
ROCE % 13.65
Total Debt to Total Equity 0.44
EBITDA Margin 12.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 120.34
ROE % 14.65
ROCE % 15.24
Total Debt to Total Equity 0.51
EBITDA Margin 11.54
Particulars MAR 2022 (Values in Cr)
Book Value / Share 104.99
ROE % 21.29
ROCE % 20.38
Total Debt to Total Equity 0.47
EBITDA Margin 14.48
Particulars MAR 2021 (Values in Cr)
Book Value / Share 92.23
ROE % 34.79
ROCE % 32.19
Total Debt to Total Equity 0.48
EBITDA Margin 21.46
Particulars MAR 2020 (Values in Cr)
Book Value / Share 266.86
ROE % 23.79
ROCE % 20.60
Total Debt to Total Equity 0.74
EBITDA Margin 15.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3.82
Total Assets 2171.61
Total Liabilities 2171.61
Total Equity 1175.20
Share Outstanding 91935000
Price to Book Ratio 3.39
Return on Assets (%) 6.53
Return on Capital (%) 8.61
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.67
Total Assets 2195.49
Total Liabilities 2195.49
Total Equity 1114.30
Share Outstanding 92600000
Price to Book Ratio 2.81
Return on Assets (%) 6.96
Return on Capital (%) 9.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.20
Total Assets 2034.52
Total Liabilities 2034.52
Total Equity 972.17
Share Outstanding 92600000
Price to Book Ratio 4.09
Return on Assets (%) 9.58
Return on Capital (%) 13.11
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.80
Total Assets 1637.00
Total Liabilities 1637.00
Total Equity 859.61
Share Outstanding 93200000
Price to Book Ratio 7.53
Return on Assets (%) 15.74
Return on Capital (%) 21.68
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.84
Total Assets 1470.69
Total Liabilities 1470.69
Total Equity 621.79
Share Outstanding 23300000
Price to Book Ratio 1.90
Return on Assets (%) 9.22
Return on Capital (%) 14.24
Particulars MAR 2024 (Values in Cr)
Net Income 235.52
Cash from Operations 421.32
Cash from Investing -223.65
Cash from Financing -136.03
Net change in Cash -0.76
Free Cash Flow 647.65
Particulars MAR 2023 (Values in Cr)
Net Income 224.18
Cash from Operations 192.99
Cash from Investing -163.97
Cash from Financing 16.54
Net change in Cash -14.10
Free Cash Flow 357.81
Particulars MAR 2022 (Values in Cr)
Net Income 269.95
Cash from Operations 153.79
Cash from Investing -149.63
Cash from Financing 92.02
Net change in Cash 12.79
Free Cash Flow 305.76
Particulars MAR 2021 (Values in Cr)
Net Income 369.01
Cash from Operations 251.62
Cash from Investing -71.77
Cash from Financing -81.12
Net change in Cash 2.04
Free Cash Flow 339.85
Particulars MAR 2020 (Values in Cr)
Net Income 185.28
Cash from Operations 291.61
Cash from Investing -33.20
Cash from Financing -215.40
Net change in Cash 2.12
Free Cash Flow 339.60
Particulars MAR 2024 (Values in Cr)
Net Income 192.48
Cash from Operations 388.33
Cash from Investing -187.09
Cash from Financing -148.80
Net change in Cash 1.20
Free Cash Flow 577.65
Particulars MAR 2023 (Values in Cr)
Net Income 204.81
Cash from Operations 216.52
Cash from Investing -131.13
Cash from Financing -30.53
Net change in Cash 0.02
Free Cash Flow 347.21
Particulars MAR 2022 (Values in Cr)
Net Income 255.49
Cash from Operations 119.98
Cash from Investing -125.35
Cash from Financing 84.11
Net change in Cash -1.35
Free Cash Flow 246.85
Particulars MAR 2021 (Values in Cr)
Net Income 337.71
Cash from Operations 241.95
Cash from Investing -69.03
Cash from Financing -85.27
Net change in Cash -0.13
Free Cash Flow 322.72
Particulars MAR 2020 (Values in Cr)
Net Income 174.97
Cash from Operations 233.46
Cash from Investing -29.35
Cash from Financing -167.75
Net change in Cash -0.96
Free Cash Flow 280.54
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 21.20 2.15 302.17 34.11 / 77.70
BLISS GVS PHARMA LTD 126.30 16.55 1.31 1330.83 92.25 / 184.95
CIPLA LTD 1551.30 25.11 4.41 125285.64 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 289.65 24.00 2.93 852.47 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 23.75 6.70 302.17 34.11 / 77.70
AMRUTAJAN HEALTH LTD 672.50 39.42 6.52 1944.24 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8961.95 133.66 32.97 22404.88 5000.00 / 9199.00
BLISS GVS PHARMA LTD 126.30 16.40 1.29 1330.83 92.25 / 184.95

AARTI DRUGS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
353.05 -3.49 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 360.80
  • 26 Days 353.00
  • 10 Days 354.90
  • 50 Days 365.20
  • 12 Days 353.50
  • 100 Days 394.10
  • 20 Days 351.80
  • 200 Days 431.10
363.05 PIVOT

First Support

360.15

First Resistance

367.50

Second Support

355.70

Second Resistance

370.40

Third Support

352.80

Third Resistance

374.85

RSI

56.56

ADX

15.47

MACD

0.56

Williams % R

-12.65

Commodity Channel Index (CCI)

123.73

Date

2025-04-24

Week

68199.00

Same Day

99011.00

Month

99861.00

1 Year

0.74

3 Year

0.65

Over 1 Month

2.69%

down

Over 1 Year

-26.93%

down

Over 3 Months

-10.74%

down

Over 3 Years

-8.45%

down

Over 6 Months

-24.55%

down

Over 5 Years

15.16%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

AARTI DRUGS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
32.57%
Promoter Holdings
55.47%
FII
2.24%
DII
9.7%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Prakash Moreshwar Patil 8504913.0 (9.32%) Shareholding of Promoter and Promoter Group
Dsp Small Cap Fund 6503593.0 (7.13%) Public Shareholding
Harshit Manilal Savla 4323269.0 (4.74%) Shareholding of Promoter and Promoter Group
Rashesh Chandrakant Gogri 4238874.0 (4.64%) Shareholding of Promoter and Promoter Group
Priti Prakash Patil 4016315.0 (4.4%) Shareholding of Promoter and Promoter Group
Seema Harshit Savla 3502175.0 (3.84%) Shareholding of Promoter and Promoter Group
Gogri Finserv Pvt. Ltd. 3463971.0 (3.8%) Shareholding of Promoter and Promoter Group
Hetal Gogri Gala 2787240.0 (3.05%) Shareholding of Promoter and Promoter Group
Harit Pragji Shah 2436908.0 (2.67%) Public Shareholding
Anushakti Enterprise Private Limited 2392696.0 (2.62%) Shareholding of Promoter and Promoter Group
Alchemie Finserv Pvt. Ltd. 2013410.0 (2.21%) Shareholding of Promoter and Promoter Group
Chandrakant Vallabhaji Gogri 1710097.0 (1.87%) Shareholding of Promoter and Promoter Group
Jayshree Harit Shah 1629076.0 (1.78%) Public Shareholding
Jaya Chandrakant Gogri 1564023.0 (1.71%) Shareholding of Promoter and Promoter Group
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund 1388523.0 (1.52%) Public Shareholding
Aashyav Business Trust (alabhya Trusteeship Private Limited) 1368429.0 (1.5%) Shareholding of Promoter and Promoter Group
Adhish P. Patil 1141079.0 (1.25%) Shareholding of Promoter and Promoter Group
Bhoomi Harshit Savla 995164.0 (1.09%) Shareholding of Promoter and Promoter Group
Vishwa Harshit Savla 939907.0 (1.03%) Shareholding of Promoter and Promoter Group
Tulip Family Trust (gloire Trusteeship Services Private Limited) 918806.0 (1.01%) Shareholding of Promoter and Promoter Group
Orchid Family Trust (relacion Trusteeship Services Private Limited) 907077.0 (0.99%) Shareholding of Promoter and Promoter Group
Aashay Rashesh Gogri 875891.0 (0.96%) Shareholding of Promoter and Promoter Group
Mirik Rajendra Gogri 641814.0 (0.7%) Shareholding of Promoter and Promoter Group
Renil Rajendra Gogri 597957.0 (0.66%) Shareholding of Promoter and Promoter Group
Paridhi Business Trust (saswat Trusteeship Private Limited) 586471.0 (0.64%) Shareholding of Promoter and Promoter Group
Safechem Enterprises Private Limited 558745.0 (0.61%) Shareholding of Promoter and Promoter Group
Dilesh Roadlines Pvt Ltd 488730.0 (0.54%) Shareholding of Promoter and Promoter Group
Jigna Hiren Shah 452597.0 (0.5%) Shareholding of Promoter and Promoter Group
Jay Manilal Savla 242060.0 (0.27%) Shareholding of Promoter and Promoter Group
Indira Madan Dedhia 193444.0 (0.21%) Shareholding of Promoter and Promoter Group
Aarnav Rashesh Gogri 186365.0 (0.2%) Shareholding of Promoter and Promoter Group
Manisha Rashesh Gogri 186763.0 (0.2%) Shareholding of Promoter and Promoter Group
Arati Tushar Sankhe 172702.0 (0.19%) Shareholding of Promoter and Promoter Group
Prakash M. Patil (huf) (karta - Prakash Moreshwar Patil) 161557.0 (0.18%) Shareholding of Promoter and Promoter Group
Arti Rajendra Gogri 137781.0 (0.15%) Shareholding of Promoter and Promoter Group
Rajendra Vallabhaji Gogri 101022.0 (0.11%) Shareholding of Promoter and Promoter Group
Arun Moreshwar Patil 72864.0 (0.08%) Shareholding of Promoter and Promoter Group
Uday Moreshwar Patil 50252.0 (0.06%) Shareholding of Promoter and Promoter Group
Alchemie Financial Services Limited 38544.0 (0.04%) Shareholding of Promoter and Promoter Group
Vikas Moreshwar Patil 34143.0 (0.04%) Shareholding of Promoter and Promoter Group
Kalika Amit Mishra 25164.0 (0.03%) Shareholding of Promoter and Promoter Group
Harshit M. Savla (huf) (karta - Harshit Manilal Savla) 5866.0 (0.01%) Shareholding of Promoter and Promoter Group
Kenisha Savla 10817.0 (0.01%) Shareholding of Promoter and Promoter Group
Hriman Savla 10817.0 (0.01%) Shareholding of Promoter and Promoter Group
Aarti Life Science Llp 13369.0 (0.01%) Shareholding of Promoter and Promoter Group
Aarti Industries Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

AARTI DRUGS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
06 Feb 2024 1.0 Interim 06 Feb 2024 Equity shares
08 Feb 2023 1.0 Interim 08 Feb 2023 Equity shares
09 Feb 2022 1.0 Interim 10 Feb 2022 Equity shares
03 Nov 2020 2.5 Interim 04 Nov 2020 Equity shares
17 Feb 2020 2.0 Interim 18 Feb 2020 Equity shares
26 Jul 2019 1.0 Final 30 Jul 2019 Equity shares
01 Aug 2018 1.0 Final 03 Aug 2018 Equity shares
09 Aug 2017 1.0 Final 11 Aug 2017 Equity shares
22 Mar 2016 3.0 Interim 3 24 Mar 2016 Equity shares
12 Feb 2016 1.5 Interim 2 15 Feb 2016 Equity shares
10 Nov 2015 2.25 Interim 14 Nov 2015 Equity shares
05 Aug 2015 3.0 Final 07 Aug 2015 Equity shares
04 Feb 2015 5.0 Interim 2 05 Feb 2015 Equity shares
19 Nov 2014 5.0 Interim 1 20 Nov 2014 Equity shares
02 Jul 2014 5.5 Final 04 Jul 2014 Equity shares
05 Feb 2014 4.5 Interim 2 06 Feb 2014 Equity shares
19 Nov 2013 3.0 Interim 14 Nov 2013 Equity shares
24 Jul 2013 4.0 Final 26 Jul 2013 Equity shares
11 Feb 2013 3.0 Interim 2 12 Feb 2013 Equity shares
05 Nov 2012 3.0 Interim 06 Nov 2012 Equity shares
17 Aug 2012 3.0 Final 22 Aug 2012 Equity shares
06 Feb 2012 2.0 Interim 07 Feb 2012 Equity shares
14 Jul 2011 2.5 Final 16 Jul 2011 Equity shares
07 Feb 2011 2.5 Interim 08 Feb 2011 Equity shares
18 Aug 2010 5.0 Final 21 Aug 2010 Equity shares
23 Jul 2009 3.0 Final 25 Jul 2009 Equity shares
13 Aug 2008 1.8 Final 16 Aug 2008 Equity shares
20 Mar 2007 1.2 Final 21 Mar 2007 Equity shares
27 Jul 2005 0.0 Final 29 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
01 Oct 2020 30 Sep 2020 3:1
25 Mar 2015 24 Mar 2015 1:1
11 Jun 1996 13 May 1996 1:2
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
06 Feb 2024 1.0 Interim 06 Feb 2024 Equity shares
08 Feb 2023 1.0 Interim 08 Feb 2023 Equity shares
09 Feb 2022 1.0 Interim 10 Feb 2022 Equity shares
03 Nov 2020 2.5 Interim 04 Nov 2020 Equity shares
17 Feb 2020 2.0 Interim 18 Feb 2020 Equity shares
26 Jul 2019 1.0 Final 30 Jul 2019 Equity shares
01 Aug 2018 1.0 Final 03 Aug 2018 Equity shares
09 Aug 2017 1.0 Final 11 Aug 2017 Equity shares
22 Mar 2016 3.0 Interim 3 24 Mar 2016 Equity shares
12 Feb 2016 1.5 Interim 2 15 Feb 2016 Equity shares
10 Nov 2015 2.25 Interim 14 Nov 2015 Equity shares
05 Aug 2015 3.0 Final 07 Aug 2015 Equity shares
04 Feb 2015 5.0 Interim 2 05 Feb 2015 Equity shares
19 Nov 2014 5.0 Interim 1 20 Nov 2014 Equity shares
02 Jul 2014 5.5 Final 04 Jul 2014 Equity shares
05 Feb 2014 4.5 Interim 2 06 Feb 2014 Equity shares
19 Nov 2013 3.0 Interim 14 Nov 2013 Equity shares
24 Jul 2013 4.0 Final 26 Jul 2013 Equity shares
11 Feb 2013 3.0 Interim 2 12 Feb 2013 Equity shares
05 Nov 2012 3.0 Interim 06 Nov 2012 Equity shares
17 Aug 2012 3.0 Final 22 Aug 2012 Equity shares
06 Feb 2012 2.0 Interim 07 Feb 2012 Equity shares
14 Jul 2011 2.5 Final 16 Jul 2011 Equity shares
07 Feb 2011 2.5 Interim 08 Feb 2011 Equity shares
18 Aug 2010 5.0 Final 21 Aug 2010 Equity shares
23 Jul 2009 3.0 Final 25 Jul 2009 Equity shares
13 Aug 2008 1.8 Final 16 Aug 2008 Equity shares
20 Mar 2007 1.2 Final 21 Mar 2007 Equity shares
27 Jul 2005 0.0 Final 29 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
01 Oct 2020 30 Sep 2020 3:1
25 Mar 2015 24 Mar 2015 1:1
11 Jun 1996 13 May 1996 1:2
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

AARTI DRUGS LTD. Share Price

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations.

The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.

The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide.

Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company.

During the year 1996-97, the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01, they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg.

During the year 2003-04, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 2004-05, the company started commercial production at their newly setup intermediate plant at Tarapur.

During the year 2005-06, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.

During the year 2006-07, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 2008-09, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg.

During the year 2009-10, the company carried out process improvement work in bulk drugs, such as antihistaminic/anti-allergic, anti-inflammatory and anti-diabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg.

A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012.

During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh.

During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs.

In 2022, the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May 2022.

Parent organization Alchemie Group
NSE symbol AARTIDRUGS
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Aarti Drugs Ltd?

Answer Field

The share price of Aarti Drugs Ltd for NSE is ₹ 350.8 and for BSE is ₹ 350.55.

What is the Market Cap of Aarti Drugs Ltd?

Answer Field

The market cap of Aarti Drugs Ltd for NSE is ₹ 32,45.80 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Aarti Drugs Ltd?

Answer Field

The 52 Week High and Low of Aarti Drugs Ltd for NSE is ₹ 635.00 and ₹ 312.00 and for BSE is ₹ 634.90 and ₹ 312.50.

How to Buy Aarti Drugs Ltd share?

Answer Field

You can trade in Aarti Drugs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Aarti Drugs Ltd?

Answer Field

The 1 year returns on the stock has been -26.93%.

What is the Current Share Price of Aarti Drugs Ltd?

Answer Field

Aarti Drugs Ltd share price is for NSE ₹ 350.8 & for BSE ₹ 350.55 as on Apr 25 2025 03:30 PM.

What is the Market Cap of Aarti Drugs Ltd Share?

Answer Field

The market cap of Aarti Drugs Ltd for NSE ₹ 32,45.80 & for BSE ₹ 0.0 as on Apr 25 2025 03:30 PM.

What is the P/E Ratio of Aarti Drugs Ltd Share?

Answer Field

As on Apr 25 2025 03:30 PM the price-to-earnings (PE) ratio for Aarti Drugs Ltd share is 25.49.

What is the PB ratio of Aarti Drugs Ltd Share?

Answer Field

As on Apr 25 2025 03:30 PM, the price-to-book (PB) ratio for Aarti Drugs Ltd share is 126.17.

How to Buy Aarti Drugs Ltd Share?

Answer Field

You can trade in Aarti Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Aarti Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Aarti Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Aarti Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|